276 related articles for article (PubMed ID: 27547884)
1. Emerging drugs for the treatment of hemophilia A and B.
Morfini M; Zanon E
Expert Opin Emerg Drugs; 2016 Sep; 21(3):301-13. PubMed ID: 27547884
[TBL] [Abstract][Full Text] [Related]
2. Safety of recombinant coagulation factors in treating hemophilia.
Morfini M; Rapisarda CAP
Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
[TBL] [Abstract][Full Text] [Related]
3. The availability of new drugs for hemophilia treatment.
Morfini M; Marchesini E
Expert Rev Clin Pharmacol; 2020 Jul; 13(7):721-738. PubMed ID: 32515633
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
Morfini M; Farrugia A
Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
[No Abstract] [Full Text] [Related]
5. Emerging drugs for hemophilia B.
Mannucci PM; Franchini M
Expert Opin Emerg Drugs; 2014 Sep; 19(3):407-14. PubMed ID: 25098797
[TBL] [Abstract][Full Text] [Related]
6. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
7. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
8. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia.
Morfini M
Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1359-1365. PubMed ID: 27677190
[TBL] [Abstract][Full Text] [Related]
10. The safety of pharmacologic options for the treatment of persons with hemophilia.
Franchini M; Mannucci PM
Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
[TBL] [Abstract][Full Text] [Related]
12. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
[TBL] [Abstract][Full Text] [Related]
13. 2017 Clinical trials update: Innovations in hemophilia therapy.
Hartmann J; Croteau SE
Am J Hematol; 2016 Dec; 91(12):1252-1260. PubMed ID: 27563744
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
Martinowitz U; Lubetsky A
Thromb Res; 2013 Mar; 131 Suppl 2():S11-4. PubMed ID: 23537721
[TBL] [Abstract][Full Text] [Related]
15. Importance of pharmacokinetics in the management of hemophilia.
Barnes C
Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
[TBL] [Abstract][Full Text] [Related]
16. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
Preijers T; van Spengler MWF; Meijer K; Fijnvandraat K; Fischer K; Leebeek FWG; Cnossen MH; Mathôt RAA
Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
[TBL] [Abstract][Full Text] [Related]
17. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
[TBL] [Abstract][Full Text] [Related]
20. Switching patients in the age of long-acting recombinant products?
Escobar M; Santagostino E; Mancuso ME; Coppens M; Balasa V; Taylor JA; Iorio A; Negrier C
Expert Rev Hematol; 2019; 12(sup1):1-13. PubMed ID: 31282771
[No Abstract] [Full Text] [Related]
[Next] [New Search]
